statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioXcel Therapeutics' Approved Drug For Bipolar Disorders/Schizophrenia Shows No Evidence Of Worsening Or Withdrawal In Post-Marketing Study

BioXcel Therapeutics shares topline results from an Igalmi (dexmedetomidine) sublingual film study. The 180 mcg dose demonstrated favorable safety and efficacy in reducing agitation symptoms.
read...

Bioxcel Therapeutics: Navigating Financial Pressures and Clinical Trials   A Hold Rating Analysis

Mizuho Securities analyst Graig Suvannavejh has maintained their neutral stance on BTAI stock, giving a Hold rating on March 13. Graig Suvannavejh...

BioXcel Therapeutics Announces $25 Million Registered Direct Offering

NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the Company ) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop...

Bioxcel Therapeutics Faces Market Estimation Risks Amidst Adoption and Access Challenges

Bioxcel Therapeutics (BTAI) has disclosed a new risk, in the Accounting & Financial Operations category. Bioxcel Therapeutics' projections of marke...

BioXcel Therapeutics (NASDAQ:BTAI) Receives "Buy" Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of BioXcel Therapeutics (NASDAQ:BTAI  Free Report) in a research note published on Monday morning, Benzinga reports. HC Wainwright currently...

Buy Rating Affirmed for BioXcel Therapeutics: FDA Pathway Clear for BXCL501 Expansion

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Bioxcel Therapeutics (BTAI Research Report) today and set a price target of $11...

BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

Newly granted patent aligns with Company's focus on expanding geographic coverage and strengthening intellectual property protection for BXCL501NEW HAVEN, Conn., March 15, 2024 (GLOBE NEWSWIRE...

BioXcel Therapeutics price target lowered by $11 at Canaccord, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Commit To Purchase BioXcel Therapeutics At $1.50, Earn 19.6% Annualized Using Options

Investors eyeing a purchase of BioXcel Therapeutics Inc (BTAI) stock, but cautious about paying the going market price of 2.78/share, might benefit from considering selling puts among the...

Q4 2023 BioXcel Therapeutics Inc Earnings Call Transcript

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Volume	259,643.00
52-Wk High	$9.77
52-Wk Low	$1.04

BTAI BioXcel Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals